| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | CL2002R563 |
| InChI Key | YRVIKLBSVVNSHF-JTQLQIEISA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C11H16N2O |
| Molecular Weight | 192.26 |
| AlogP | 1.52 |
| Hydrogen Bond Acceptor | 3.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 34.15 |
| Molecular species | BASE |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 14.0 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor alpha subunit
|
- | - | - | 16-39 | - | |
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor beta subunit
|
- | - | - | 16-39 | - | |
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor delta subunit
|
30000 | - | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Alzheimer Disease | 2 | D000544 | ClinicalTrials |
| Attention Deficit Disorder with Hyperactivity | 2 | D001289 | ClinicalTrials |
| Tobacco Use Disorder | 2 | D014029 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL127071 |
| DrugBank | DB05458 |
| EPA CompTox | DTXSID20167149 |
| FDA SRS | CL2002R563 |
| PubChem | 178052 |
| SureChEMBL | SCHEMBL194037 |
| ZINC | ZINC000000006562 |